Thermo Fisher Scientific invites clients at all points on their pathway to commercialization, whether they’re an emerging biotech developing a rare disease therapy or a high-volume pharmaceutical manufacturer to learn about how we are continuing to drive strategic investments in expertise, flexibility and scale to meet growing demand.

Join us for a live webcast that will announce our progress on the 2020 investments to our Pharma Services business and provide focused insight on our expanding gene therapy capabilities.

We will also cover an update on our strategy to ensure the delivery of drugs to customers and patients in lieu of the COVID-19 outbreak, as well as our evolving direct response to the virus through several ongoing projects.

Featured Speakers

Mike Shafer

Senior Vice President and President, Pharma Services
Thermo Fisher Scientific

Mike Shafer joined Pharma Services in October of 2019. Mike has an 11-year track record of leading businesses within Thermo Fisher including Thermo Fisher China, the Chemical Analysis business, and the Materials & Structural analysis business following the acquisition of FEI. Mike has an intense commitment to customers, operational focus and ability to build strong teams.

Chris Murphy

Vice President and General Manager, Viral Vector Services
Thermo Fisher Scientific

Christopher Murphy is Vice President and General Manager of Viral Vector Services in Thermo Fisher Scientific’s Pharma Services Group. Prior to joining Thermo Fisher, Chris served as chief operating officer for Brammer Bio, a leading viral vector/gene therapy CDMO.  Chris has more than 30 years of experience in biopharmaceutical manufacturing, process development, plant operations, and quality system implementation. 

NOW AVAILABLE ON-DEMAND

Register now for this webinar